Repligen (RGEN) Receives Research Grants to Support Friedreich's Ataxia Development Program
Tweet Send to a Friend
Repligen Corporation (Nasdaq: RGEN) announced that Repligen has received $1.125 million in research grants to support the development of new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
